Drugs / Promensil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03844685 | Jul 2012 → Mar 2014 | breast cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Promensil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03844685 ↗ |
| Known as | MCE-11 | “1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months” NCT03844685 ↗ |
| Route | Oral | “taken orally” NCT03844685 ↗ |